Clinical Trials (Phase IV)
Found 3,372 articles
Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer’s (SITC) 33RD Annual Meeting
Personalis, Inc. will present new data at the upcoming Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting, taking place in Washington, D.C., November 9-11, 2018.
The United Kingdom is calling for greater clinical trial transparency after a government committee released a report that indicates that data from about half of all clinical trials in that country are not published, raising concerns over research integrity and risks to human health.
Analysis of data shows fulvestrant did not meet bioequivalence criteria
First Patient Screened in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
Mallinckrodt plc today confirmed screening of the first patient in the company's Phase 4, multi-center, multiple-dose, open label study to assess the effects of H.P. Acthar Gel as a therapy option in patients with Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis (NIPPU).
Mallinckrodt Presents Data on H.P. Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting
Phase 4 study interim analysis showed 61% of patients with persistently active RA reported in the open-label period achieved low disease activity at 12 weeks
Leica Microsystems introduces new PROVIDO multidisciplinary surgical microscope at leading otolaryngology conference in Atlanta
Acerus Announces Publication of Manuscript Reporting Early Data from Partner-Sponsored Natesto® Spermatogenesis Study
Early Data Suggests Sperm Concentration, Motility, and Total Motile Sperm Count Remain Within Normal Ranges in Hypogonadal Men Taking Natesto®
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
- INPULSIS®-ON study indicates safety and efficacy of Ofev® (nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS trials
DoctorLogic ranks 317 out of 5,000 fastest-growing private companies with a total growth of more than 1,500% since its launch.
New technology destroys deadly pathogens and bacteria lurking on hospital surfaces
Eisai Inc. Announces Positive Topline Results from CAMELLIA-TIMI 61, a Large-Scale Cardiovascular Outcome Trial for the Anti-Obesity Agent BELVIQ®
BELVIQ did not increase incidence of cardiovascular events in study of 12,000 obese and overweight patients
A report recently published by the National Academies of Sciences, Engineering, and Medicine concluded that institutions and researchers should regularly and carefully evaluate whether and how to provide study results to participants.
Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)
Cannabics Pharmaceuticals Inc. announced that it has concluded its clinical trial held at Rambam Medical Center.
PQ Bypass Reports Positive 12-Month Results for Entirely New Procedure to Treat Extremely Long SFA Lesions in Patients with PAD
DETOUR I Trial Presented during SVS Vascular Annual Meeting 2018 Late Breaking Clinical Trial Session
WCG (WIRB-Copernicus Group) Clinical Services Division Partners with InformedDNA to Help Sponsors Design and Execute More Effective Clinical Trials
Companies join forces to deliver new solutions that optimize genetics in clinical trials in the era of precision medicine.
SetPoint Medical Reports Positive Long-term Results from its Clinical Study of Bioelectronic Medicine to Treat Rheumatoid Arthritis
Results presented at Annual European Congress of Rheumatology highlight strong therapy adherence and significant reduction in rheumatoid arthritis symptoms after 24-months of therapy.
Mallinckrodt Reports Interim Findings Of H.P. Acthar® Gel (Repository Corticotropin Injection) Studies
Rheumatoid Arthritis Phase 4 Clinical Trial Data Recently Presented at the Annual European Congress of Rheumatology
Genentech’s hemophilia treatment Hemlibra continues to demonstrate its efficacy in treating patients. New late-stage data presented at World Federation of Hemophilia 2018 World Congress shows the drug significantly reduced treated bleeds in a broad patient population in two separate studies.
NaviGate Cardiac Structures Inc. (“NCSI”) reports “excellent valvular function” at 1-year follow-up of first patient to receive GATE™ tricuspid valved stent via transjugular access
This first transjugular implantation of the GATE ™ tricuspid valved stent occurred at the Cleveland Clinic in April 2017
LumiThera Inc. presented topline final results from the LIGHTSITE I clinical trial for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System.